Literature DB >> 32330423

Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.

Deepak Bararia1, Johannes A Hildebrand1, Sebastian Stolz2, Sarah Haebe2, Stefan Alig2, Christopher P Trevisani3, Francisco Osorio-Barrios4, Michael D Bartoschek5, Michael Mentz2, Alessandro Pastore6, Erik Gaitzsch1, Michael Heide1, Vindi Jurinovic7, Katharina Rautter8, Jay Gunawardana9, Muhammed B Sabdia9, Monika Szczepanowski10, Julia Richter10, Wolfram Klapper10, Abner Louissaint11, Christina Ludwig12, Sebastian Bultmann5, Heinrich Leonhardt5, Sebastian Eustermann13, Karl-Peter Hopfner13, Wolfgang Hiddemann1, Michael von Bergwelt-Baildon1, Christian Steidl14, Robert Kridel14, Joshua W D Tobin9, Maher K Gandhi9, David M Weinstock3, Marc Schmidt-Supprian15, Menyhárt B Sárosi16, Martina Rudelius17, Verena Passerini1, Josef Mautner18, Oliver Weigert19.   

Abstract

Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional, and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from an enzymatically inactive profrom to active CTSS and increased substrate cleavage, including CD74, which regulates major histocompatibility complex class II (MHC class II)-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cell activation; antigen processing and presentation; cathepsin S; cysteine-protease; follicular lymphoma; immune microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32330423     DOI: 10.1016/j.celrep.2020.107522

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  13 in total

1.  Phenylephrine increases tear cathepsin S secretion in healthy murine lacrimal gland acinar cells through an alternative secretory pathway.

Authors:  Runzhong Fu; Srikanth Janga; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2021-09-03       Impact factor: 3.770

Review 2.  Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.

Authors:  Michael R Cook; Kieron Dunleavy
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

3.  Integrated Multiomics Analysis Identifies a Novel Biomarker Associated with Prognosis in Intracerebral Hemorrhage.

Authors:  Yiqing Shen; Wensong Yang; Xin Xiong; Xinhui Li; Zhongsong Xiao; Jialun Yu; Fangyu Liu; Siwen Gui; Xiongfei Xie; Fajin Lv; Libo Zhao; Liangbo Hu; Anatol Manaenko; Peng Xie; Qi Li
Journal:  Oxid Med Cell Longev       Date:  2021-12-14       Impact factor: 7.310

4.  EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Authors:  M K Gandhi; T Hoang; S C Law; S Brosda; K O'Rourke; J W D Tobin; F Vari; V Murigneux; L Fink; J Gunawardana; C Gould; H Oey; K Bednarska; S Delecluse; R U Trappe; L Merida de Long; M B Sabdia; G Bhagat; G Hapgood; E Blyth; L Clancy; J Wight; E Hawkes; L M Rimsza; A Maguire; K Bojarczuk; B Chapuy; C Keane
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

Review 5.  Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery.

Authors:  Natalie Fuchs; Mergim Meta; Detlef Schuppan; Lutz Nuhn; Tanja Schirmeister
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 6.  Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.

Authors:  Cèlia Dobaño-López; Ferran Araujo-Ayala; Neus Serrat; Juan G Valero; Patricia Pérez-Galán
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

Review 7.  The follicular lymphoma epigenome regulates its microenvironment.

Authors:  Rada Amin; Mounia S Braza
Journal:  J Exp Clin Cancer Res       Date:  2022-01-12

8.  Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment.

Authors:  Liyuan Song; Xianhui Wang; Wang Cheng; Yi Wu; Min Liu; Ruizi Liu; Shenyi Zhang; Hong Xia; Hao Liu; Xuejiao Tai; Huzi Zhao; Xihua Li; Fuyun Ji
Journal:  BMC Pulm Med       Date:  2021-12-20       Impact factor: 3.317

9.  Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S.

Authors:  Lingwei Kong; Hairu Ji; Xintian Gan; Sheng Cao; Zhehong Li; Yu Jin
Journal:  J Orthop Surg Res       Date:  2022-03-09       Impact factor: 2.359

Review 10.  Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.

Authors:  Noushin Mossadegh-Keller; Gabriel Brisou; Alicia Beyou; Bertrand Nadel; Sandrine Roulland
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.